2026/2945(DEA)

Delegated Regulation on EMA Fees Inflation Adjustment

Gedelegeerde verordening van de Commissie tot wijziging van de bijlagen I tot en met IV bij Verordening (EU) 2024/568 van het Europees Parlement en de Raad wat betreft de aanpassing aan de inflatie van de aan het Europees Geneesmiddelenbureau te betalen vergoedingen en heffingen per 1 januari 2027

Summary

Generated

Commission delegated regulation amending Annexes I–IV of Regulation (EU) 2024/568 to adjust fees and charges payable to the European Medicines Agency for inflation, applying from 1 January 2027. It affects pharmaceutical companies and other applicants filing marketing-authorization and related procedures with the EMA, and the agency's fee revenue.

What the workspace adds on this file

Everything above is the public record. In the workspace, subscribers see this file with their own layer on top.

Why it matters to you

What this file means for your organization, assessed against your own priorities.

What moved

When this file moves, it reaches your own briefing, with a link to its source.

Your contacts on it

Your team's contacts logged against this file: who you met, what was said and the next step.

A first draft

A statement, a member update or a meeting brief on this file, in your organization's voice, with its sources.

Sources: EP Legislative Observatory. Record as of 27 Oct 2026. Something wrong on this page? Report an error.

Request access

See this file with your own layer on top: why it matters to you, your contacts on it and a first draft. We’ll schedule a 20-minute walkthrough.

Hosted in the EU · Security →

By submitting, you agree to our privacy policy.